Alx Oncology Holdings Inc
ALXO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.17
KIRA · Stoqly’s AI analyst, in plain words
- Alx Oncology Holdings Inc lost $102M in fiscal 2025.
- Free cash flow was −$84.4M in fiscal 2025, — of revenue.
- Alx Oncology Holdings Inc has $33.1M more cash than debt.
Market cap
$159M
P/E
—
Revenue
—
Net income
−$102M
Free cash flow
−$84.4M
Operating margin
—
Alx Oncology Holdings Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$102M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alx Oncology Holdings Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- ALX ONCOLOGY HOLDINGS INC
- CIK
- 0001810182
Alx Oncology Holdings Inc · ALXO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | — | — | — |
| Revenue growth | −100.0% | — | — | — | — |
| Net income | −$83.5M | −$123M | −$161M | −$135M | −$102M |
| Diluted EPS | −$2.07 | −$3.03 | −$3.74 | −$2.58 | −$1.90 |
| Cash | |||||
| Cash from operations | −$68.1M | −$89.2M | −$130M | −$122M | −$84.1M |
| Capital expenditure | $0.7M | $1.4M | $1.3M | $0.4M | $0.2M |
| Free cash flow | −$68.8M | −$90.7M | −$132M | −$122M | −$84.4M |
| Share count change | 118.1% | 1.0% | 5.6% | 21.4% | 2.8% |
| Debt and strength | |||||
| Cash and short-term investments | $364M | $266M | $183M | $128M | $44.8M |
| Debt incl. finance leases | — | $10.9M | $12.9M | $13.3M | $11.7M |
| Shareholders' equity | $363M | $263M | $190M | $114M | $26.0M |
| Current ratio | 24.0x | 9.6x | 5.2x | 7.3x | 2.1x |
| Interest coverage | −6,427.3x | −535.4x | −108.8x | −82.4x | −64.9x |
| Returns and quality | |||||
| Return on capital | — | −1,281.3% | −765.4% | — | — |
| Return on equity | −21.1% | −39.4% | −71.0% | −88.9% | −145.7% |
| Return on tangible equity | −23.0% | −46.9% | −84.8% | −118.7% | −391.4% |
| Piotroski F-score | 1 | 1 | 1 | 2 | 1 |
| Altman Z'' | 25.1 | 5.4 | −3.4 | −11.5 | −48.0 |
Insiders bought, 12 months
$5.0M
1 insider
Insiders sold, 12 months
$0.0M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alx Oncology Holdings Inc · ALXO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.17 a share, the company is worth $159M.
Source: SEC EDGAR XBRL filings (CIK 0001810182). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.